TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...
Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.
CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...
The funding will be put towards an early feasibility study, designed to determine the clinical effectiveness and safety of Laplace’s transcatheter tricuspid valve replacement system. If successful, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback